Glycosylated extracellular matrix drives immune suppression by modulating macrophage-T cell crosstalk in triple-negative breast cancer.
Saved in:
| Title: | Glycosylated extracellular matrix drives immune suppression by modulating macrophage-T cell crosstalk in triple-negative breast cancer. |
|---|---|
| Authors: | Tarantola L; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK., Tyler EJ; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK., Liu Y; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK., Maniati E; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK., Thornton KA; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK., Martín-Otal C; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK., Hanna D; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK., Kumar R; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK., Gauthier V; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK., Hirani P; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK., Burger Ramos M; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK., Roth NJ; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK., Bragg J; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK., Puttock EH; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK., McDermott J; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK., Rajeeve V; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK., Cutillas P; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK., Maiques O; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK., Soulier A; Neobe Therapeutics, Salisbury House, Station Road, Cambridge, UK., Correa de Sampaio P; Neobe Therapeutics, Salisbury House, Station Road, Cambridge, UK., Jones LJ; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK., Davies DM; Leucid Bio, Guy's Hospital, Great Maze Pond, London, UK., Maher J; Leucid Bio, Guy's Hospital, Great Maze Pond, London, UK., Haslam SM; Department of Life Sciences, Imperial College London, London, UK., Läubli H; Department of Biomedicine and Division of Medical Oncology, University Hospital Basel, Basel, Switzerland., Pearce OMT; Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK. o.pearce@qmul.ac.uk. |
| Source: | Nature communications [Nat Commun] 2026 Jun 16; Vol. 17 (1). Date of Electronic Publication: 2026 Jun 16. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-026-73467-5 |
